- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Starpharma Holdings Limited (ASX: SPL) today announced that it has received notification of the grant in the US of a key patent specifically relating to the use of SPL7013 to protect against sexually transmitted infections (STIs).
The granting of this patent means that any product presentation of SPL7013 (the active ingredient in VivaGel(R) ) is now protected in the US for an additional five years until 2024, with a possible further 12 month extension to 2025. Given the importance of genital herpes and other STIs in the US, this market is clearly a major commercial opportunity for VivaGel(R) products.
This composition of matter patent is the third patent for VivaGel(R) to be granted in the US, and adds to the already extensive patent coverage for the product in 26 countries covering all major markets.
VivaGel(R) is being developed as a condom coating in collaboration with SSL International plc (LSE: SSL) , the world's leading condom company. SSL markets the global brand Durex(R), and holds approximately 40% of the global branded condom market. Following a deal announced in 2008, SSL has exclusive marketing rights for the VivaGel(R) coated condom.
Starpharma is also developing VivaGel(R) as a vaginal microbicide to prevent the transmission of STIs, including HIV and genital herpes.
Starpharma Holdings Limited (ASX: SPL) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA.
The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. In September 2008 Starpharma signed a full licence agreement with SSL International plc (LSE: SSL) to develop a VivaGel(R) coated condom. Starpharma's receipts under the agreement are estimated to exceed A$100m comprising royalties on SSL sales, further milestone payments, and development support.
For more information, please click here
Tel: +61 3 9866 4722
Mob: +61 417 382 391
Tel: +61 2 9237 2800
Dr Jackie Fairley
Chief Executive Officer
+61 3 8532 2704
+61 3 8532 2702
Copyright © PrNewswireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
CAP-XX Launches 0.6mm Thinline Supercapacitors for Designing Wearable, Ultra-Portable and Connected IoT Devices: Eliminated Materials and Changed Processes to Reduce Thickness and Costs to Below $1 May 19th, 2015
Iran Unveils 6 Knowledge-Based Products April 11th, 2015
Researchers develop new way to manufacture nanofibers May 21st, 2015
Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015
Application of Egg White in Production of Nanoparticles April 6th, 2015
Sunblock poses potential hazard to sea life August 20th, 2014
This Slinky lookalike 'hyperlens' helps us see tiny objects: The photonics advancement could improve early cancer detection, nanoelectronics manufacturing and scientists' ability to observe single molecules May 23rd, 2015